Bioshares put out an extensive piece on QRx earlier this...

Bioshares put out an extensive piece on QRx earlier this week.
They painted 3 scenarios, the best of which was approval Feb 2013 based on QRx only having to resubmit additional data alongside reformatted data from the initial submission. Both other case scenarios involved more trials, the worst of which was approval March 2014 and involved a repeat of Study 008 with bigger numbers.

Obviously it's all up in the air until the August meeting where QRx finds out what it needs to do from the FDA to make Mox Duo IR an approvable drug.